Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02035527 · ClinicalTrials.gov registry record · Phase 1
Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
A Phase 1 study of Recurrent Salivary Gland Cancer and Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, sponsored by Ohio State University Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
- 1
- Study location
NCT02035527 is a Phase 1 study of Recurrent Salivary Gland Cancer and Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma that has completed, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 3 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02035527, a Phase 1 study of Recurrent Salivary Gland Cancer and Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, has completed, sponsored by Ohio State University Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I/II trial studies the side effects and the best dose of sorafenib tosylate and docetaxel when given together with cisplatin and to see how well they work in treating patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib tosylate may also help cisplatin and docetaxel work better by making tumor cells more sensitive to the drugs. Giving sorafenib tosylate, cisplatin, and docetaxel may be an effective treatment for squamous cell carcinoma of the head and neck.
Conditions Studied
Interventions
- DRUG cisplatin
- DRUG docetaxel
- DRUG sorafenib tosylate
- OTHER Correlative Studies
Study Locations (1)
Ohio
- Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2014-04-14 |
| Est. Completion | 2017-04-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02035527
The ClinicalTrials.gov registry entry for NCT02035527 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University Comprehensive Cancer Center, which has 341 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Recurrent Salivary Gland Cancer appearing as the primary indexed condition, and to 4 interventions - of which cisplatin is the first listed.
NCT02035527 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT02035527 about?
NCT02035527 is a clinical study titled "Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck". This phase I/II trial studies the side effects and the best dose of sorafenib tosylate and docetaxel when given together with cisplatin and to see how well they work in treating patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Drugs used in chemotherapy, such as ci...
What is the current status of trial NCT02035527?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2014-04-14. Estimated completion is 2017-04-20.
What conditions does trial NCT02035527 study?
This clinical trial studies the following conditions: Recurrent Salivary Gland Cancer, Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity.
What interventions are being tested in trial NCT02035527?
The interventions under investigation include: cisplatin (DRUG), docetaxel (DRUG), sorafenib tosylate (DRUG), Correlative Studies (OTHER).
Who is sponsoring clinical trial NCT02035527?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02035527 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Salivary Gland Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Recurrent Salivary Gland Cancer
All registered trials for this condition
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
All registered trials for this condition
Ohio
All trials with a study site in Ohio
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.